# Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

> **NCT03150056** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 73 (actual)

## Conditions studied

- Solid Tumours

## Interventions

- **DRUG:** GSK525762
- **DRUG:** Abiraterone
- **DRUG:** Enzalutamide
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT03150056
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-18
- **Primary completion:** 2020-07-31
- **Final completion:** 2021-06-22
- **Target enrollment:** 73 (ACTUAL)
- **Why stopped:** This study has been terminated due to meeting protocol defined futility.
- **Last updated:** 2022-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03150056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03150056, "Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03150056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*